T. Rowe Price Amends 13G—Owns 1,025,868 SLNO Shares

T. Rowe Price Associates, Inc. filed an Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 1,025,868 shares of Soleno Therapeutics common stock, representing 2.0% of the class.

Rhea-AI Filing Summary

T. Rowe Price Associates, Inc. filed an Amendment No. 2 to a Schedule 13G/A reporting beneficial ownership of 1,025,868 shares of Soleno Therapeutics common stock, representing 2.0% of the class. The filing lists 1,025,117 shares with sole voting power and was signed on 05/15/2026.

The filer also includes a standard disclaimer denying beneficial ownership in the filing language. The disclosure updates the issuer name, CUSIP 834203309, and the reporter's address for regulatory recordkeeping.

Insights

Institutional Ownership Analyst

Institutional holder reports a 2.0% stake in Soleno Therapeutics.

The amendment confirms T. Rowe Price Associates holds 1,025,868 shares representing 2.0% of outstanding common stock and records sole voting power on 1,025,117 shares. This is a routine regulatory disclosure required for sizable passive holdings.

Cash‑flow treatment and intent are not stated in the excerpt; subsequent filings would show changes in position. Regulatory records (CUSIP 834203309) and the reporter's signature date 05/15/2026 are provided.

Compliance & Filings Specialist

Amendment format and disclaimer are standard for Schedule 13G/A filings.

The filing includes the required ownership breakdown: sole voting power, sole dispositive power, and percent of class. It also contains the common Schedule 13G/A disclaimer denying beneficial ownership, which is a legal precaution sometimes used by investment managers.

Investors should track future amendments for any material position changes; this filing itself is administrative and does not state trading intent.

Key Figures

Beneficially owned: 1,025,868 shares Percent of class: 2.0% Sole voting power: 1,025,117 shares +1 more

4 metrics

Beneficially owned 1,025,868 shares Amount beneficially owned reported on the amendment

Percent of class 2.0% Percent of common stock reported in Item 4(b)

Sole voting power 1,025,117 shares Number of shares with sole power to vote reported in Item 4(c)(i)

CUSIP 834203309 Identifier for Soleno Therapeutics common stock

Key Terms

Schedule 13G/A, Beneficial ownership, Sole Dispositive Power

3 terms

Schedule 13G/A regulatory

"Amendment No. 2 to Schedule 13G/A reporting beneficial ownership"

A Schedule 13G/A is an amended public filing with the U.S. securities regulator that updates a previous Schedule 13G, disclosing when an individual or group holds a substantial (typically over 5%) stake in a company and is claiming a passive, non‑controlling intent. Investors monitor these updates because rising or falling holdings can signal changing confidence, potential future moves, or shifts in voting power — like watching a public ledger where large shareholders quietly adjust their positions.

Beneficial ownership financial

"Amount beneficially owned: 1025868 (b) Percent of class: 2.0 %"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

Sole Dispositive Power regulatory

"Sole Dispositive Power 1,025,868.00 listed in the ownership breakdown"

Sole dispositive power is the exclusive legal authority to decide what happens to a security — for example, whether to sell, transfer, or retain shares — without needing anyone else’s permission. Investors care because it signals who truly controls the economic outcome of an investment: like holding the only key to a safe, the holder can realize gains or losses and may trigger regulatory reporting, insider rules, or influence over corporate ownership.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many Soleno Therapeutics (SLNO) shares does T. Rowe Price report?

T. Rowe Price reports 1,025,868 shares of Soleno Therapeutics common stock, representing 2.0% of the class. The filing also shows 1,025,117 shares with sole voting power as of the amendment.

What form did T. Rowe Price file for its SLNO holding disclosure?

The firm filed an Amendment No. 2 to Schedule 13G/A, the regulatory form for passive institutional holdings. The filing includes ownership breakdowns and a signature dated 05/15/2026.

Does the Schedule 13G/A indicate T. Rowe Price plans to sell SLNO shares?

No disposition intent is stated in the excerpt. The filing lists voting and dispositive powers and includes a disclaimer denying beneficial ownership; it does not disclose any planned sales or purchases.

What CUSIP and issuer details are included for SLNO in the filing?

The filing lists the issuer as Soleno Therapeutics Inc with CUSIP 834203309 and the issuer address at 100 Marine Parkway, Suite 400, Redwood City, CA 94065 for regulatory identification.

When was the Schedule 13G/A amendment signed by T. Rowe Price?

The amendment is signed by Ellen York, Vice President, with the signature date shown as 05/15/2026, which serves as the filing's attestation date for the ownership figures disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/15/2026 - 10:07 AM EDT Learn about SEC filing dates

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 2)

SOLENO THERAPEUTICS INC

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

834203309

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

schemaVersion:

SCHEDULE 13G

CUSIP Number(s): 834203309

1

Names of Reporting Persons

T. Rowe Price Associates, Inc.

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

MARYLAND

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 1,025,117.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 1,025,868.00
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

1,025,868.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

2.0 %

12

Type of Reporting Person (See Instructions)

IA

SCHEDULE 13G

Item 1.
(a)	Name of issuer: SOLENO THERAPEUTICS INC
(b)	Address of issuer's principal executive offices: 100 MARINE PARKWAY, SUITE 400, REDWOOD CITY, CA, 94065
Item 2.
(a)	Name of person filing: T. Rowe Price Associates, Inc.
(b)	Address or principal business office or, if none, residence: 1307 Point Street, Baltimore, MD 21231
(c)	Citizenship: Maryland
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 834203309
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 1025868
(b)	Percent of class: 2.0 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: 1025117
	(ii) Shared power to vote or to direct the vote: 0
	(iii) Sole power to dispose or to direct the disposition of: 1025868
	(iv) Shared power to dispose or to direct the disposition of: 0
Item 5.	Ownership of 5 Percent or Less of a Class.
	Ownership of 5 percent or less of a class
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. T. Rowe Price Associates, Inc. hereby declares and affirms that the filing of Schedule 13G shall not be construed as an admission that Price Associates is the beneficial owner of the securities referred to, which beneficial ownership is expressly denied.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

T. Rowe Price Associates, Inc.

Signature:	Ellen York
Name/Title:	Vice President
Date:	05/15/2026